From the Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System, Buffalo, NY.
In this issue of THE JOURNAL, Preston and colleagues1
argue that pharmacokinetic and pharmacodynamic modeling applied prospectively
to a clinical trial of a fluoroquinolone antibiotic aids in understanding
the efficacy and safety of therapy. The investigators used modeling to link
bacterial eradication to the individual minimum inhibitory concentration (MIC)
values of the bacteria, and the individual serum concentrations (ie, peak
concentration or the area under the curve [AUC]) of the antibiotic in the
treated patient. The article presents considerable evidence that the prospective
use of these modeling methods in the course of a multicenter antibiotic trial
can identify a dose that will ensure efficacy and can predict when a regimen
will not work or will select resistant subpopulations of organisms.
Schentag JJ. Antibiotic Dosing—Does One Size Fit All?. JAMA. 1998;279(2):159-160. doi:10.1001/jama.279.2.159